Guang-Zhi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guang-Zhi Liu has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Lin Ma
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
10 shared publicationsZe-Xin Fan
Department of Neurology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
10 shared publicationsTing-Ting Yang
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
8 shared publicationsTian-Tong Niu
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
7 shared publications- Ting-Ting Yang
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
7 shared publications Bo-Yi Yuan
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People’s Republic of China
6 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 17 (12)
Cardiac myxoma and its implications for cardioembolic stroke
Cardiac myxoma (CM) is the most common type of primary cardiac tumor and a major embolic source of cardioembolic stroke. Two potential causative mechanisms are associated with CM-related ischemic stroke (CM-IS): Embolism from detached tumor debris and metastatic infiltration. The risk factors for embolism from CM remain unclear and are widely debated in the literature. CM-IS often initially presents with central nervous system complications. Diagnosis requires a comprehensive assessment of clinical manifestations, imaging findings, and laboratory test results, with histopathological examination required for a definitive diagnosis. Surgical resection of myxoma is the most effective CM-IS treatment, although the optimal timing and approach remain controversial. This review consolidates the current knowledge on CM-IS, identifies critical risk factors for embolic complications, and discusses contemporary treatment strategies, emphasizing the need for individualized management protocols and further research to improve outcomes in affected patients.
- 26 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 17 (12)
Open AccessCardiac myxoma and its implications for cardioembolic stroke
Cardiac myxoma (CM) is the most common type of primary cardiac tumor and a major embolic source of cardioembolic stroke. Two potential causative mechanisms are associated with CM-related ischemic stroke (CM-IS): Embolism from detached tumor debris and metastatic infiltration. The risk factors for embolism from CM remain unclear and are widely debated in the literature. CM-IS often initially presents with central nervous system complications. Diagnosis requires a comprehensive assessment of clinical manifestations, imaging findings, and laboratory test results, with histopathological examination required for a definitive diagnosis. Surgical resection of myxoma is the most effective CM-IS treatment, although the optimal timing and approach remain controversial. This review consolidates the current knowledge on CM-IS, identifies critical risk factors for embolic complications, and discusses contemporary treatment strategies, emphasizing the need for individualized management protocols and further research to improve outcomes in affected patients.
- Open Access
- 26 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 17 (11) , 109941
Neurocardiology - from basics to clinic
Neurocardiology is an interdisciplinary field that studies the interactions between the nervous and cardiovascular systems, encompassing research across the entire spectrum, from molecular mechanisms to clinical diagnosis and treatment. The disease types in neurocardiology include several major categories: Involvement of the nervous and cardiovascular systems caused by common factors, involvement of the cardiovascular system caused by neuropsychiatric abnormalities, and involvement of the nervous system caused by cardiovascular abnormalities. Routine and special examinations are needed during the diagnostic process. The simultaneous management of brain and heart conditions is the core strategy, which advocates multidisciplinary collaboration, communication, and interaction. Herein, we review studies on the pathophysiological mechanisms, clinical manifestations, and new advances in diagnosis and treatment in the field of neurocardiology, particularly the latest research progress of traditional Chinese medicine, and further propose the construction of an integrated healthcare service system for future research.
- 26 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 17 (11) , 109941
Open AccessNeurocardiology - from basics to clinic
Neurocardiology is an interdisciplinary field that studies the interactions between the nervous and cardiovascular systems, encompassing research across the entire spectrum, from molecular mechanisms to clinical diagnosis and treatment. The disease types in neurocardiology include several major categories: Involvement of the nervous and cardiovascular systems caused by common factors, involvement of the cardiovascular system caused by neuropsychiatric abnormalities, and involvement of the nervous system caused by cardiovascular abnormalities. Routine and special examinations are needed during the diagnostic process. The simultaneous management of brain and heart conditions is the core strategy, which advocates multidisciplinary collaboration, communication, and interaction. Herein, we review studies on the pathophysiological mechanisms, clinical manifestations, and new advances in diagnosis and treatment in the field of neurocardiology, particularly the latest research progress of traditional Chinese medicine, and further propose the construction of an integrated healthcare service system for future research.
- Open Access
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Open AccessGlobal, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (31) , e43552
Immune checkpoint inhibitors associated inflammatory disease of central nervous system: Case report and systemic review
Rationale: The use of immune checkpoint inhibitors (ICIs) has greatly improved the outcomes of cancer. However, ICI-induced immune-related adverse events have been reported, among which neurological immune-related adverse events are rare but potentially life-threatening. To analyze the characteristics of ICI-induced inflammatory disease of the central nervous system (CNS), we reported the first case induced by tislelizumab and conducted a systematic review of 33 cases. Patient concerns: A 65-year-old male patient who received 4 cycles of tislelizumab for lung squamous carcinoma developed myelitis, demyelinating encephalopathy, and peripheral neuropathy overlap syndrome. Case reports and case series that described ICI-associated inflammatory disease of the CNS in the PubMed and Embase databases were searched up to October 2022. Diagnoses: The patient was diagnosed with ICI-associated neuroimmune overlap syndrome, including myelitis, peripheral neuropathy, and multifocal demyelinating encephalopathy. Interventions: The patient was treated with intravenous methylprednisolone. Outcomes: The symptoms alleviated gradually. Twenty-six publications that described 33 cases with ICI-associated inflammatory disease of the CNS were reviewed. In addition to the present case, only 8 cases with both brain and spinal cord lesions induced by ICIs were reported. Intravenous steroids were the first-line therapy, while plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and some monoclonal antibodies may be effective for steroid-refractory neurological immune-related adverse events. Thirteen patients experienced relapse, and 4 patients died, one of whom committed suicide. Lessons: ICI-associated inflammatory disease of the CNS is very rare, but we should be aware of and detect it to treat timely manner and achieve a good prognosis.
- 1 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (31) , e43552
Open AccessImmune checkpoint inhibitors associated inflammatory disease of central nervous system: Case report and systemic review
Rationale: The use of immune checkpoint inhibitors (ICIs) has greatly improved the outcomes of cancer. However, ICI-induced immune-related adverse events have been reported, among which neurological immune-related adverse events are rare but potentially life-threatening. To analyze the characteristics of ICI-induced inflammatory disease of the central nervous system (CNS), we reported the first case induced by tislelizumab and conducted a systematic review of 33 cases. Patient concerns: A 65-year-old male patient who received 4 cycles of tislelizumab for lung squamous carcinoma developed myelitis, demyelinating encephalopathy, and peripheral neuropathy overlap syndrome. Case reports and case series that described ICI-associated inflammatory disease of the CNS in the PubMed and Embase databases were searched up to October 2022. Diagnoses: The patient was diagnosed with ICI-associated neuroimmune overlap syndrome, including myelitis, peripheral neuropathy, and multifocal demyelinating encephalopathy. Interventions: The patient was treated with intravenous methylprednisolone. Outcomes: The symptoms alleviated gradually. Twenty-six publications that described 33 cases with ICI-associated inflammatory disease of the CNS were reviewed. In addition to the present case, only 8 cases with both brain and spinal cord lesions induced by ICIs were reported. Intravenous steroids were the first-line therapy, while plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and some monoclonal antibodies may be effective for steroid-refractory neurological immune-related adverse events. Thirteen patients experienced relapse, and 4 patients died, one of whom committed suicide. Lessons: ICI-associated inflammatory disease of the CNS is very rare, but we should be aware of and detect it to treat timely manner and achieve a good prognosis.
- Open Access
CD4+CD25+ regulatory T cell therapy in neurological autoimmune diseases
CD4+CD25+ regulatory T cells (Tregs) play a critical role in maintaining immune tolerance. They are essential for the initiation and progression of autoimmune diseases affecting the nervous system. Recently, the correlation between Tregs and neurological autoimmune diseases, as well as their therapeutic potential, has become a central focus of research. Currently, various methods for in vivo or in vitro generation and expansion of CD4+CD25+ Tregs are under investigation; however, their application in cellular therapy is anticipated to face additional challenges. This article primarily delves into the development and function of CD4+CD25+ Tregs, the role of Tregs in neurological autoimmune disease pathology, basic methods for enhancing therapies, and recent advancements and challenges in cellular therapy for neurological autoimmune diseases.
Open AccessCD4+CD25+ regulatory T cell therapy in neurological autoimmune diseases
CD4+CD25+ regulatory T cells (Tregs) play a critical role in maintaining immune tolerance. They are essential for the initiation and progression of autoimmune diseases affecting the nervous system. Recently, the correlation between Tregs and neurological autoimmune diseases, as well as their therapeutic potential, has become a central focus of research. Currently, various methods for in vivo or in vitro generation and expansion of CD4+CD25+ Tregs are under investigation; however, their application in cellular therapy is anticipated to face additional challenges. This article primarily delves into the development and function of CD4+CD25+ Tregs, the role of Tregs in neurological autoimmune disease pathology, basic methods for enhancing therapies, and recent advancements and challenges in cellular therapy for neurological autoimmune diseases.
- Open Access
- 16 January 2025
- Published by Springer Nature in Scientific Data
- Vol. 12 (1) , 1-12
lncRNA, miRNA, and mRNA of plasma and tumor-derived exosomes of cardiac myxoma-related ischaemic stroke
Cardiac myxoma (CM) is an important aetiology of stroke in young adults, and its diagnosis is difficult in patients having stroke because of the lack of diagnostic biomarkers. Tumour-derived exosomes play a crucial role in tumour growth, metastasis, immune regulation, and monitor disease development. Hence,we established an RNA-sequencing dataset for long non-coding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA) in the plasma and tumour-derived exosomes from four patients with cardiac myxoma-related ischaemic stroke (CM-IS) and six patients with cardiac myxoma without ischaemic stroke (non-IS CM). Moreover, 5,533 lncRNAs, 1,331 known miRNAs, and 412 new miRNAs were identified. Finally, gene expression profiles and differentially expressed genes were analysed in 20 samples. In the plasma samples, 74 miRNAs, 12 lncRNAs, and 693 mRNAs were identified, while tumour-derived tissue samples contained 61 miRNAs, 67 lncRNAs, and 433 mRNAs. This dataset provides a significant resource for relevant researchers to explore the potential dysregulated lncRNAs, miRNAs, and mRNAs of plasma and tumour-derived exosomes in CM-IS.
- 16 January 2025
- Published by Springer Nature in Scientific Data
- Vol. 12 (1) , 1-12
Open AccesslncRNA, miRNA, and mRNA of plasma and tumor-derived exosomes of cardiac myxoma-related ischaemic stroke
Cardiac myxoma (CM) is an important aetiology of stroke in young adults, and its diagnosis is difficult in patients having stroke because of the lack of diagnostic biomarkers. Tumour-derived exosomes play a crucial role in tumour growth, metastasis, immune regulation, and monitor disease development. Hence,we established an RNA-sequencing dataset for long non-coding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA) in the plasma and tumour-derived exosomes from four patients with cardiac myxoma-related ischaemic stroke (CM-IS) and six patients with cardiac myxoma without ischaemic stroke (non-IS CM). Moreover, 5,533 lncRNAs, 1,331 known miRNAs, and 412 new miRNAs were identified. Finally, gene expression profiles and differentially expressed genes were analysed in 20 samples. In the plasma samples, 74 miRNAs, 12 lncRNAs, and 693 mRNAs were identified, while tumour-derived tissue samples contained 61 miRNAs, 67 lncRNAs, and 433 mRNAs. This dataset provides a significant resource for relevant researchers to explore the potential dysregulated lncRNAs, miRNAs, and mRNAs of plasma and tumour-derived exosomes in CM-IS.
- Open Access
- 19 November 2024
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 24 (1) , 1-12
Risk factors and prediction model for acute ischemic stroke after off-pump coronary artery bypass grafting based on Bayesian network
This study aimed to identify the risk factors of acute ischemic stroke (AIS) occurring during hospitalization in patients following off-pump coronary artery bypass grafting (OPCABG) and utilize Bayesian network (BN) methods to establish predictive models for this disease. Data were collected from the electronic health records of adult patients who underwent OPCABG at Beijing Anzhen Hospital from January 2018 to December 2022. Patients were allocated to the training and test sets in an 8:2 ratio according to the principle of randomness. Subsequently, a BN model was established using the training dataset and validated against the testing dataset. The BN model was developed using a tabu search algorithm. Finally, receiver operating characteristic (ROC) and calibration curves were plotted to assess the extent of disparity in predictive performance between the BN and logistic models. A total of 10,184 patients (mean (SD) age, 62.45 (8.7) years; 2524 (24.7%) females) were enrolled, including 151 (1.5%) with AIS and 10,033 (98.5%) without AIS. Female sex, history of ischemic stroke, severe carotid artery stenosis, high glycated albumin (GA) levels, high D-dimer levels, high erythrocyte distribution width (RDW), and high blood urea nitrogen (BUN) levels were strongly associated with AIS. Type 2 diabetes mellitus (T2DM) was indirectly linked to AIS through GA and BUN. The BN models exhibited superior performance to logistic regression in both the training and testing sets, achieving accuracies of 72.64% and 71.48%, area under the curve (AUC) of 0.899 (95% confidence interval (CI), 0.876–0.921) and 0.852 (95% CI, 0.769–0.935), sensitivities of 91.87% and 89.29%, and specificities of 72.35% and 71.24% (using the optimal cut-off), respectively. Female gender, IS history, carotid stenosis (> 70%), RDW-CV, GA, D-dimer, BUN, and T2DM are potential predictors of IS in our Chinese cohort. The BN model demonstrated greater efficiency than the logistic regression model. Hence, employing BN models could be conducive to the early diagnosis and prevention of AIS after OPCABG.
- 19 November 2024
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 24 (1) , 1-12
Open AccessRisk factors and prediction model for acute ischemic stroke after off-pump coronary artery bypass grafting based on Bayesian network
This study aimed to identify the risk factors of acute ischemic stroke (AIS) occurring during hospitalization in patients following off-pump coronary artery bypass grafting (OPCABG) and utilize Bayesian network (BN) methods to establish predictive models for this disease. Data were collected from the electronic health records of adult patients who underwent OPCABG at Beijing Anzhen Hospital from January 2018 to December 2022. Patients were allocated to the training and test sets in an 8:2 ratio according to the principle of randomness. Subsequently, a BN model was established using the training dataset and validated against the testing dataset. The BN model was developed using a tabu search algorithm. Finally, receiver operating characteristic (ROC) and calibration curves were plotted to assess the extent of disparity in predictive performance between the BN and logistic models. A total of 10,184 patients (mean (SD) age, 62.45 (8.7) years; 2524 (24.7%) females) were enrolled, including 151 (1.5%) with AIS and 10,033 (98.5%) without AIS. Female sex, history of ischemic stroke, severe carotid artery stenosis, high glycated albumin (GA) levels, high D-dimer levels, high erythrocyte distribution width (RDW), and high blood urea nitrogen (BUN) levels were strongly associated with AIS. Type 2 diabetes mellitus (T2DM) was indirectly linked to AIS through GA and BUN. The BN models exhibited superior performance to logistic regression in both the training and testing sets, achieving accuracies of 72.64% and 71.48%, area under the curve (AUC) of 0.899 (95% confidence interval (CI), 0.876–0.921) and 0.852 (95% CI, 0.769–0.935), sensitivities of 91.87% and 89.29%, and specificities of 72.35% and 71.24% (using the optimal cut-off), respectively. Female gender, IS history, carotid stenosis (> 70%), RDW-CV, GA, D-dimer, BUN, and T2DM are potential predictors of IS in our Chinese cohort. The BN model demonstrated greater efficiency than the logistic regression model. Hence, employing BN models could be conducive to the early diagnosis and prevention of AIS after OPCABG.
- Open Access
- 14 June 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (6) , 215
Impact of Concurrent Ischaemic Stroke on Unfavourable Outcomes in Men and Women with Dilated Cardiomyopathy
Background: Growing evidence suggests that concurrent ischaemic stroke (IS) exacerbates the prognosis of patients with dilated cardiomyopathy (DCM) and that this effect may be further influenced by sex. However, the exact effect of sex remains unclear. This study aimed to explore the effects of the relevant risk factors on the prognosis of patients with DCM and concurrent IS. Considering the sex differences in DCM, this study further investigated the impact of concurrent IS on the prognosis of men and women with DCM. Methods: A total of 632 patients with DCM enrolled between 2016 and 2021 were included in this study. Clinical data were obtained from medical records, and all participants were followed up in the outpatient clinic or by telephone for at least 1 year. A Cox proportional hazards model and Kaplan–Meier curves were used to evaluate the effects of concurrent IS on the prognosis of patients with DCM. Results: Patients with DCM complicated with IS (DCM-IS) had significantly lower cumulative survival rates than patients with DCM without IS (non-IS) (74.6% vs. 84.2%, χ2 = 6.85, p = 0.009). Additionally, IS was associated with greater risks of death and heart transplantation (HTx) in men (75.8% vs. 85.1%, χ2 = 5.02, p = 0.025), but not in women (71.0% vs. 81.5%, χ2 = 1.91, p = 0.167). Conclusions: This large-scale multicentre prospective cohort study demonstrated a poorer prognosis in patients with concurrent DCM and IS, particularly among men. Patients with DCM should not be overlooked in IS screening, emphasis should be placed on the occurrence of IS in patients with DCM. Early and proactive secondary prevention of cerebrovascular diseases might improve the prognosis of DCM patients. More intervention studies focusing on men with DCM complicated with IS should be prioritised.
- 14 June 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (6) , 215
Open AccessImpact of Concurrent Ischaemic Stroke on Unfavourable Outcomes in Men and Women with Dilated Cardiomyopathy
Background: Growing evidence suggests that concurrent ischaemic stroke (IS) exacerbates the prognosis of patients with dilated cardiomyopathy (DCM) and that this effect may be further influenced by sex. However, the exact effect of sex remains unclear. This study aimed to explore the effects of the relevant risk factors on the prognosis of patients with DCM and concurrent IS. Considering the sex differences in DCM, this study further investigated the impact of concurrent IS on the prognosis of men and women with DCM. Methods: A total of 632 patients with DCM enrolled between 2016 and 2021 were included in this study. Clinical data were obtained from medical records, and all participants were followed up in the outpatient clinic or by telephone for at least 1 year. A Cox proportional hazards model and Kaplan–Meier curves were used to evaluate the effects of concurrent IS on the prognosis of patients with DCM. Results: Patients with DCM complicated with IS (DCM-IS) had significantly lower cumulative survival rates than patients with DCM without IS (non-IS) (74.6% vs. 84.2%, χ2 = 6.85, p = 0.009). Additionally, IS was associated with greater risks of death and heart transplantation (HTx) in men (75.8% vs. 85.1%, χ2 = 5.02, p = 0.025), but not in women (71.0% vs. 81.5%, χ2 = 1.91, p = 0.167). Conclusions: This large-scale multicentre prospective cohort study demonstrated a poorer prognosis in patients with concurrent DCM and IS, particularly among men. Patients with DCM should not be overlooked in IS screening, emphasis should be placed on the occurrence of IS in patients with DCM. Early and proactive secondary prevention of cerebrovascular diseases might improve the prognosis of DCM patients. More intervention studies focusing on men with DCM complicated with IS should be prioritised.
- Open Access
- 15 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
CD4+CD25+ regulatory T cells ex vivo generated from autologous naïve CD4+ T cells suppress EAE progression
CD4+CD25+ regulatory T cells (Tregs) play an important role in maintaining immune homeostasis in multiple sclerosis (MS). Hence, we aimed to explore the therapeutic efficacy and safety of adoptive cell therapy (ACT) utilizing induced antigen-specific Tregs in an animal model of MS, that is, in an experimental autoimmune encephalomyelitis (EAE) model. B cells from EAE model that were activated with soluble CD40L were used as antigen-presenting cells (APCs) to induce the differentiation of antigen-specific Tregs from naïve CD4 precursors, and then, a stepwise isolation of CD4+CD25highCD127low Tregs was performed using a flow sorter. All EAE mice were divided into Treg-treated group (2 × 104 cells in 0.2 mL per mouse, n = 14) and sham-treated group (0.2 mL normal saline (NS), n = 20), which were observed daily for clinical assessment, and for abnormal appearance for 6 weeks. Afterward, histological analysis, immunofluorescence and real-time PCR were performed. Compared to sham-treated mice, Treg-treated mice exhibited a significant decrease in disease severity scores and reduced inflammatory infiltration and demyelination in the spinal cord. Additionally, Tregs-treated mice demonstrated higher CCN3 protein and mRNA levels than sham-treated mice. The results of this preclinical study further support the therapeutic potential of this ACT approach in the treatment of MS.
- 15 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessCD4+CD25+ regulatory T cells ex vivo generated from autologous naïve CD4+ T cells suppress EAE progression
CD4+CD25+ regulatory T cells (Tregs) play an important role in maintaining immune homeostasis in multiple sclerosis (MS). Hence, we aimed to explore the therapeutic efficacy and safety of adoptive cell therapy (ACT) utilizing induced antigen-specific Tregs in an animal model of MS, that is, in an experimental autoimmune encephalomyelitis (EAE) model. B cells from EAE model that were activated with soluble CD40L were used as antigen-presenting cells (APCs) to induce the differentiation of antigen-specific Tregs from naïve CD4 precursors, and then, a stepwise isolation of CD4+CD25highCD127low Tregs was performed using a flow sorter. All EAE mice were divided into Treg-treated group (2 × 104 cells in 0.2 mL per mouse, n = 14) and sham-treated group (0.2 mL normal saline (NS), n = 20), which were observed daily for clinical assessment, and for abnormal appearance for 6 weeks. Afterward, histological analysis, immunofluorescence and real-time PCR were performed. Compared to sham-treated mice, Treg-treated mice exhibited a significant decrease in disease severity scores and reduced inflammatory infiltration and demyelination in the spinal cord. Additionally, Tregs-treated mice demonstrated higher CCN3 protein and mRNA levels than sham-treated mice. The results of this preclinical study further support the therapeutic potential of this ACT approach in the treatment of MS.
- Open Access
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1294229
A Bayesian network-based approach for identifying risk factors and predicting ischemic stroke in infective endocarditis patients
Objective: This study aimed to seek the risk factors and develop a predictive model for ischemic stroke (IS) in patients with infective endocarditis (IE) utilizing a Bayesian network (BN) approach.Methods: Data were obtained from the electronic medical records of all adult patients at three hospitals between 1 January 2018, and 31 December 2022. Two predictive models, logistic regression and BN, were used. Patients were randomly assigned to the training and test sets in a 7:3 ratio. We established a BN model with the training dataset and validated it with the testing dataset. The Bayesian network model was built by using the Tabu search algorithm. The areas under the receiver operating characteristic curve (AUCs), calibration curve, and decision curve were used to evaluate the prediction performance between the BN and logistic models.Results: A total of 542 patients [mean (SD) age, 49.6 (15.3) years; 137 (25.3%) female] were enrolled, including 151 (27.9%) with IS and 391 (72.1%) without IS. Hyperlipidemia, hypertension, age, vegetation size (>10 mm), S. aureus infection, and early prosthetic valve IE were closely correlated with IS. The BN models outperformed the logistic regression in training and testing sets, with accuracies of 76.06% and 74.1%, AUC of 0.744 and 0.703, sensitivities of 25.93% and 20.93%, and specificities of 96.27% and 90.24%, respectively.Conclusion: The BN model is more efficient than the logistic regression model. Therefore, BN models may be suitable for the early diagnosis and prevention of IS in IE patients.
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1294229
Open AccessA Bayesian network-based approach for identifying risk factors and predicting ischemic stroke in infective endocarditis patients
Objective: This study aimed to seek the risk factors and develop a predictive model for ischemic stroke (IS) in patients with infective endocarditis (IE) utilizing a Bayesian network (BN) approach.Methods: Data were obtained from the electronic medical records of all adult patients at three hospitals between 1 January 2018, and 31 December 2022. Two predictive models, logistic regression and BN, were used. Patients were randomly assigned to the training and test sets in a 7:3 ratio. We established a BN model with the training dataset and validated it with the testing dataset. The Bayesian network model was built by using the Tabu search algorithm. The areas under the receiver operating characteristic curve (AUCs), calibration curve, and decision curve were used to evaluate the prediction performance between the BN and logistic models.Results: A total of 542 patients [mean (SD) age, 49.6 (15.3) years; 137 (25.3%) female] were enrolled, including 151 (27.9%) with IS and 391 (72.1%) without IS. Hyperlipidemia, hypertension, age, vegetation size (>10 mm), S. aureus infection, and early prosthetic valve IE were closely correlated with IS. The BN models outperformed the logistic regression in training and testing sets, with accuracies of 76.06% and 74.1%, AUC of 0.744 and 0.703, sensitivities of 25.93% and 20.93%, and specificities of 96.27% and 90.24%, respectively.Conclusion: The BN model is more efficient than the logistic regression model. Therefore, BN models may be suitable for the early diagnosis and prevention of IS in IE patients.